John A Taylor, III, MD, is a professor and director of basic urologic research and the coleader of the D3ET Program at the University of Kansas Medical Center. A native of New York, he completed his medical degree at Columbia University’s College of Physicians and Surgeons in New York City, where he stayed to complete his internship and residency in general surgery and urology. He subsequently served for three years on active duty at Walter Reed Army Medical Center, where he was director of medical education for urology and assistant professor at Uniformed Services University of the Health Sciences (USUHS). After completing his military obligation, he took a faculty position at the University of Connecticut Health Center during which time he completed a master’s degree in clinical and translation science and was promoted to professor.
Dr. Taylor is an avid translational researcher with an active lab that pursues novel drug discovery/therapeutics for bladder cancer. He has enjoyed continued extramural funding inclusive of grants and philanthropic donations since 2005. These have included a Jahnigen Scholars Award from the American Geriatrics Society, an American Geriatrics Society/John A. Hartford Foundation Geriatrics Education for Specialty Residents educational grant, an American Cancer Society Mentored Research Scholar Award and a National Institutes of Health R01 as a co-investigator. Most recently, his lab and research have been supported by continual philanthropic donation from the Albert Charitable Trust. His work has been recognized by multiple peer-reviewed publications and several U.S. provisional/full patents. In addition, he is engaged in clinical trials exploring new therapeutics for treatment of bladder cancer.
Dr. Taylor has served on numerous regional and national committees. While at University of Connecticut, he was on the Institutional Review Board (IRB) and was chair of the Cancer Committee. He was on the New England section of the American Urological Association (AUA) Scientific Review Committee and Judicial and Ethics Committee, with appointment as chair with representation to the AUA, and the board of directors for five years. He was selected for and graduated from the AUA’s leadership class, served on the AUA Young Urologist Committee and is on the AUA Research Council with most recent appointment to the Research Grants and Investigator Support Workgroup. He was invited to partake in the 35th Anniversary Steering Committee of the AUA Foundation, the National Urological Research Agenda Planning Group and the National Institutes of Health/NIDDK Urology 2.0 Working Group. In addition, he was a participant in the National Cancer Institute’s Bladder Cancer Task Force for Clinical Trial Development and the Society for Immunotherapy of Cancer, Cancer Immunotherapy Guidelines – Genitourinary-Bladder Task Force. He was appointed to the editorial board of the Journal of Urology and is a member of the Bladder Cancer Research Network Management Committee, which oversees the research and development arm of the Bladder Cancer Advocacy Network. He also acts as an external reviewer for the FDA committee on novel treatment of bladder cancer. Most recently, he founded the Leo and Anne Albert Institute for Bladder Cancer and Research, where he is president and director.
Dr. Taylor’s practice focuses on caring for and treating patients with bladder cancer.